Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed CentralRead more →

Stage I ER-positive PR-negative breast cancer: disease-free after lumpectomy, radiation and tamoxifen

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER 2+ in 60% of tumor cells; PR-negative; HER2/neu-negative; Ki-67 5%; 0/6 lymph nodes positive

At 15 months after surgery, she was disease-free, had no complaints, and was satisfied with the surgical result.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Luminal A solid papillary breast carcinoma with lung metastasis: mastectomy and lung resection, PET-CT clear

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial breast tumor and lung metastasis were ER/PR positive, HER2 0

Metastatic Site: lung

About 40 days after lung surgery, PET-CT showed no abnormalities; the specialist recommended regular follow-up without additional antitumor drug therapy, and she was alive and in good condition.

PubMed CentralRead more →

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed CentralRead more →

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Breast cancer survivorship complicated by fatal lymphedema-associated necrotizing soft tissue infection

Patient Info: Anonymized, Female, 50s

Biomarkers: Prior breast cancer: ER-positive, PR-positive, HER2-negative

She died after hospital-acquired pneumonia and acute respiratory failure during recovery from severe right-arm lymphedema-associated necrotizing soft tissue infection after prior breast cancer treatment.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage 3 breast cancer: complete pathological response to chemotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

At 1-year follow-up, she remained free of breast cancer; a thyroid nodule found on CT had no malignancy on fine-needle aspiration.

PubMed CentralRead more →

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer AllianceRead more →

Stage 2 secretory breast cancer: surgery alone with clear margins

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PR-negative; HER2-negative; secretory carcinoma; low grade

At 1-month follow-up after modified radical mastectomy, she had no surgical site infection, no arm lymphedema, no scapular winging, full shoulder range of motion, and no evidence of nodal or distant disease.

PubMed CentralRead more →

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of HopeRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer AllianceRead more →